Background Mitral valve repair (MVr) is the gold standard treatment for degenerative mitral regurgitation, yet there is ...

Stopping blood thinners before or during surgery for a CIED may result in little to no difference in undesirable outcomes such as blood clots or bleeding events when compared to taking them ...

Updates in new antiplatelet therapies, new patient populations for PCI and AI to guide CAD staging were among the top ...

Jefferies analyst Stephen Barker maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on January 19 and set a price ...

A recent study by researchers from the University of Toronto, Tyndale University and the University of Texas at Arlington found that older adults are at greater risk of having a stroke if they ...

Objectives: We aimed to study the correlation of TG with rivaroxaban, apixaban, and edoxaban drug concentrations in a large, prospective multicenter cross-sectional study. Methods: Five-hundred and ...

Edoxaban monotherapy reduced net adverse clinical events compared with edoxaban plus a single antiplatelet agent, when used as long-term antithrombotic therapy, in patients with high-risk atrial ...

Apixaban is currently indicated in Europe for the prevention of VTE in patients who have undergone total knee replacement or total hip replacement. Apixaban is also being investigated in Phase III ...

A total of 12.2% (n=8566) of all patients were treated with either rivaroxaban, apixaban, edoxaban, or dabigatran with intake <48 hours of admission. IVT was administered in 21.5% of all patients ...

Primary end point Efficacy end point is symptomatic stroke/systemic embolism Definition of the safety end point of bleeding differs across trials Prothrombin time international normalized ratio ...